Health Trials

About this trial

The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ \_stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.

Eligibility criteria

Qualifiers

Patients aged ≥ 18 years AND;

Patients who according to standard practice of the hospital are amenable to PCI as indicated and considered adequate according to the European clinical practice guidelines on coronary revascularization AND;

Patients with at least one lesion fulfilling the "long lesion criteria" suitable for a single stent approach AND;

Patients who have been informed of the characteristics of the study and have provided written informed consent AND;

Disqualifiers

Patients who expressly decline to participate in the study.

Pregnant or breastfeeding women.

Patients with acute coronary syndrome (ACS) under conditions of cardiogenic shock (Killip class 4).

Patients with contraindications or hypersensitivity to sirolimus.

Trial design

Treatments tested in this trial

  • LONG NAGOMI

Treatment groups

1,039 Participants
are divided into 1 treatment group

Locations

7
Hospital Universitario de Cabueñes33394, Cabueñes Spain
Hospital General Universitario de Elche03203, Elche Spain
Hospital Universitario Juan Ramón Jiménez21005, Huelva Spain
Hospital Universitario de Leon24008, León Spain

Sponsors and collaborators

Fundación EPIC

Lead sponsor

Source ClinicalTrials.gov